Dissolving Lip Fillers: Hyaluronidase Treatment for Correction

Understanding Hyaluronidase: Mechanism and Clinical Application

Hyaluronidase, an enzyme naturally occurring in animal tissues, catalyzes breakdown of hyaluronic acid polymers into smaller oligosaccharide units, effectively dissolving hyaluronic acid fillers. The enzyme cleaves glycosidic bonds in the hyaluronic acid polymer chain, reducing high-molecular-weight HA (typically 500,000-1,000,000 daltons in fillers) into small degradation products rapidly absorbed and metabolized by tissue. This mechanism allows practitioners to reverse or partially reverse hyaluronic acid filler results when patients are dissatisfied with outcomes, experience complications, or require correction of previous treatment. Hyaluronidase is supplied as Vitrase (150 units/mL, Ista Pharmaceuticals) or Wydase (150 units/mL, American Medical Systems), both approved by FDA for ophthalmic use; however, off-label use for dermal filler dissolution has become standard cosmetic practice. Hyaluronidase is supplied as powder requiring reconstitution with provided diluent; once reconstituted, solution should be used immediately or within 5 minutes for optimal enzyme activity.

Indications for Hyaluronidase Filler Dissolution

Hyaluronidase treatment is indicated when patients experience dissatisfaction with hyaluronic acid filler results, require correction of asymmetry, or experience complications requiring filler removal. Common indications include: obvious overfilling creating disproportionate appearance, asymmetric filler distribution requiring rebalancing, filler migration into perioral areas creating unwanted appearance, allergic reaction or granulomatous response to fillers, and vascular occlusion requiring immediate filler removal. Patients may also seek dissolution when reconsidering previous treatment decisions or preferring return to baseline appearance. Hyaluronidase should not be used to dissolve non-HA fillers including calcium hydroxylapatite (Radiesse), polylactic acid (Sculptra), or silicone products; different complications from these fillers require distinct management approaches.

Pre-Treatment Assessment and Planning

Thorough assessment before hyaluronidase application determines treatment strategy and outcome expectations. Careful examination determines whether filler overfilling, asymmetry, or migration represents primary concern guiding whether total or partial dissolution is optimal. Patients should be counseled that hyaluronidase works quickly (24-48 hours) with continued improvement through week 2; visual softening of results becomes apparent within 24 hours. Photography documenting baseline appearance before hyaluronidase allows objective assessment of treatment effect. Patient expectations must be clarified; hyaluronidase provides definitive dissolution rather than modest reduction, and overdissolution creating underfilled appearance is possible. If partial correction is desired (softening results while maintaining modest volume), lower hyaluronidase doses allow graduated dissolution rather than complete product removal.

Injection Technique and Dosing Protocols

Hyaluronidase injection technique and dosing influence treatment outcomes. Direct injection into areas of visible filler burden (overfilled lips, perioral migration) is most effective; injecting hyaluronidase systemically (via IV) is impractical for cosmetic applications. Typical dosing for lip filler dissolution ranges 10-50 units depending on filler volume being dissolved; excessive dosing creates unnecessary risk of complete product loss and potential tissue deflation. Initial treatment typically uses 20-30 units total, distributed as 5-10 unit aliquots injected into concentrated filler areas using 30-gauge needle. Injections target visible firmness or palpable product bulges. Multiple injection sites separated by 5-10 mm allow even enzyme distribution and graduated dissolution preventing localized over-dissolution. Reconstituted hyaluronidase should be used immediately; delayed application (> 5 minutes) reduces enzyme activity and effectiveness.

Post-Injection Appearance and Timeline

Hyaluronidase produces visible effects more rapidly than other cosmetic procedures. Within 1-2 hours post-injection, visible softening of treated areas becomes apparent as hyaluronic acid begins degrading. By 12 hours post-injection, substantial reduction in filler firmness and bulk is evident. Peak dissolution effect occurs at 24-48 hours when enzymatic breakdown reaches maximum and partially dissolved product is resorbed into tissue. Final appearance assessment should be performed at 48-72 hours; however, continued subtle improvement may occur through week 2 as residual product fragments are completely metabolized. Significant overfilling that required hyaluronidase reversal typically shows 70-90% volume reduction by 48 hours. Minor overfilling may show more modest 30-50% reduction, allowing some volume retention. Patients should be aware that transient underfilling may appear during dissolution phase as expected; final appearance becomes apparent when process completes.

Partial Dissolution and Volume Adjustment

Some patients desire partial dissolution rather than complete filler removal. Low-dose hyaluronidase application (5-15 units total) produces graduated dissolution softening results without complete product elimination. This approach helps correct asymmetry without losing all volume gains, or reduces overfilled appearance while maintaining moderate enhancement. Partial dissolution typically requires follow-up assessment at 1 week; if additional dissolution is needed, repeat hyaluronidase injection at 1-2 week interval allows measured approach. Conservative initial dosing reducing risk of overdissolution is preferred to aggressive dosing creating underfilled appearance requiring additional filler injection.

Complications and Safety Considerations

Hyaluronidase is well-tolerated with minimal adverse effects when properly applied. Post-injection erythema, edema, and minor bruising occur in 5-10% of treatments, resolving within 24-48 hours. Ecchymosis (bruising) may be more pronounced with hyaluronidase than standard filler injection due to multiple injection sites. Vasovagal response occasionally occurs with hyaluronidase injection; patients should be reclined and reassured. Allergic reaction to hyaluronidase is rare (< 0.1%) but possible; practitioners should have epinephrine readily available. Vascular injury risk exists with hyaluronidase as with any injection; however, hyaluronidase does not create vascular occlusion itself. Overdissolution creating underfilled appearance is iatrogenic complication from excessive hyaluronidase dosing; this may require additional filler injection to address. Sensory changes or dysesthesia occasionally follow hyaluronidase injection if injections are placed near sensitive nerve areas; this typically resolves within 2-4 weeks.

Timing and Retreat Considerations

Hyaluronidase is most effective when used relatively soon after filler injection while products have not fully integrated into tissue. Dissolution of fillers injected within 2 weeks is most complete (> 90% removal); dissolution of fillers injected 4+ weeks previously shows reduced efficacy (70-80% removal) as partial integration limits enzyme access. Fillers injected 3+ months previously may show minimal response (< 50% reduction) as complete tissue integration limits enzyme effectiveness. Therefore, hyaluronidase should be applied promptly if patients want complete dissolution; delayed application reduces effectiveness. However, even delayed application typically achieves meaningful reduction compared to baseline filled appearance.

Cost and Patient Decision-Making

Hyaluronidase treatment cost typically ranges $300-$600 depending on units required and practitioner location. This cost represents modest additional investment for patients who had filler placed elsewhere and seek correction. Practitioners should be transparent regarding hyaluronidase costs before using them; some patients find it difficult to accept paying additional fees after investing substantially in initial filler treatment. However, hyaluronidase availability provides valuable service allowing patients to correct or reverse decisions without permanent commitment to filler appearance. This ability to reverse treatment may encourage patients toward filler treatment they might otherwise avoid due to fear of permanent change.

References